Hollen C W, Henthorn J, Koziol J A, Burstein S A
University of Oklahoma Health Sciences Center, Oklahoma City 73109.
Leuk Lymphoma. 1992 Oct;8(3):235-41. doi: 10.3109/10428199209054910.
Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using an IL-6-responsive bioassay. A cohort of healthy volunteers with normal platelet counts was used to establish a control mean serum IL-6 level [2.19 U/ml +/- 1.08 SD (range 0-5.5)]. Patients with primary thrombocytosis had a mean serum IL-6 level not significantly different from controls. In comparison, serum IL-6 levels of patients with reactive thrombocytosis were significantly greater than controls (38.3 U/ml +/- 94.6; range 0-933; P < 0.001). Although no significant correlation was observed between the degree of serum IL-6 elevation and the height of the platelet count in any individual, elevated serum IL-6 was highly correlated with reactive thrombocytosis.
白细胞介素-6（IL-6）已被证实在多种动物模型中可增加血小板计数，并在体外增强巨核细胞生成。为了研究IL-6与血小板增多症之间的可能关系，采用IL-6反应性生物测定法检测了血小板计数≥6×10⁵/微升患者的血清IL-6水平。选取一组血小板计数正常的健康志愿者来确定对照血清IL-6平均水平[2.19 U/ml±1.08 SD（范围0 - 5.5）]。原发性血小板增多症患者的血清IL-6平均水平与对照组无显著差异。相比之下，反应性血小板增多症患者的血清IL-6水平显著高于对照组（38.3 U/ml±94.6；范围0 - 933；P<0.001）。虽然在任何个体中血清IL-6升高程度与血小板计数高度之间均未观察到显著相关性，但血清IL-6升高与反应性血小板增多症高度相关。
